The HECA Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma line, featuring targeted disruption of the HECA gene. This loss-of-function model facilitates the study of HECA??s tumor-suppressive role as a negative regulator of Wnt/??-catenin signaling. The polyclonal format retains genetic heterogeneity, enabling the investigation of gene function in a diverse cell pool that better recapitulates intratumoral variability than clonal cell lines.
The A-549 parental cell line was established from the lung adenocarcinoma of a 58-year-old Caucasian male and grows as adherent epithelial cells. It serves as a widely used alveolar type II pneumocyte model for NSCLC research. A-549 carries an activating KRAS p.G12S mutation and a homozygous deletion of the CDKN2A tumor suppressor, while retaining wild-type TP53. These genetic features make it a valuable system for exploring signaling crosstalk in lung cancer.
HECA protein functions as a transcriptional corepressor by directly binding TCF4 (TCF7L2) to prevent its association with CTNNB1 (??-catenin), thus repressing transcription of Wnt target genes such as CCND1 (Cyclin D1) and MYC (c-Myc). Within the canonical Wnt pathway, HECA is downstream of the ligand WNT3A and is negatively regulated by miR-197. By interfering with the TCF4/??-catenin complex, HECA inhibits cell cycle progression and proliferation. The knockout of HECA in these cells alleviates this repression, leading to activation of Wnt signaling that can be measured by standard reporter assays.
In the A-549 background, the HECA knockout model enables functional dissection of the interplay between Wnt/??-catenin signaling and the KRAS-driven oncogenic program, along with the loss of CDKN2A. Since HECA is frequently downregulated in hepatocellular carcinoma, colorectal cancer, and lung adenocarcinoma, this system is suitable for rescue experiments and epistasis analyses to interrogate cooperative tumorigenic mechanisms. It provides a platform to evaluate how HECA loss modifies proliferation and tumorigenicity in the context of established lung cancer mutations.
Experimental applications include Wnt pathway profiling via TOP/FOP Flash luciferase reporter assays, protein?Cprotein interaction studies by co-immunoprecipitation of HECA with TCF4, and quantitative analysis of downstream effectors (??-catenin, c-Myc, Cyclin D1) through Western blotting or RT-qPCR. Functional assessments can be performed using MTT proliferation assays and colony formation tests. Additionally, the model supports drug screening for Wnt/??-catenin inhibitors, as HECA disruption sensitizes cells to pathway modulation. For further technical information or to discuss customized protocols, please contact Ascent Research.
